About the SPORE
The University of Iowa/Mayo Clinic Lymphoma SPORE conducts innovative, interactive, translational research on lymphoma, chronic lymphocytic leukemia and small lymphocytic lymphoma.
The Lymphoma SPORE leverages the combined strengths of the translational lymphoma programs of the University of Iowa Holden Comprehensive Cancer Center and the Mayo Clinic Cancer Center — two National Cancer Institute (NCI)-designated comprehensive cancer centers. At Mayo Clinic, the Lymphoma SPORE is part of the Hematologic Malignancies Program, a formal research program within the Mayo Clinic Cancer Center.
Investigators in the Lymphoma SPORE have made numerous research advances to help find better treatments for lymphoma, chronic lymphocytic leukemia and small lymphocytic lymphoma. They've identified new tumor markers, made discoveries that led to additional translational lymphoma grants from the NCI, published multiple manuscripts, and accrued dozens of patients to clinical trials.
The Lymphoma SPORE patient database now includes more than 8,000 patients. The outcome data from these patients have led to the development of novel response biomarkers that have improved clinical care for patients with lymphoma and helped in the design of new clinical trials.
The Lymphoma SPORE has four active research projects:
- Activating Phagocytic Macrophages in Non-Hodgkin Lymphoma
- Microenvironment Modification and Anti-PD1 Immunotherapy of Lymphoma
- Targeting Tumor Metabolism in Lymphoma
- Genomic Predictors of Early Relapse in Immunochemotherapy-Treated Follicular Lymphoma
Explore the SPORE's research projects.
The University of Iowa/Mayo Clinic Lymphoma SPORE was first funded by the NCI in 2002, and funding was competitively renewed in 2007, 2012 and 2017. A SPORE, or Specialized Program of Research Excellence, is a cornerstone of the NCI's efforts to promote collaborative, interdisciplinary translational cancer research.
The principal investigators for the University of Iowa/Mayo Clinic Lymphoma SPORE are: